1-15 of 15
Sharyn D. Baker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Daelynn Buelow, Xining Yang, Deedra Nicolet, Krzysztof Mrózek, Kathrin Krowiorz, Raj Bhayadia, Jack Stromatt, Anna Denny, Christoph Wiegel, Colin Corbett, Salma Abdelbaky, Yonger Xue, Yizhou Dong, Jeremy Hui, Arshia Shad, Sharon Gao, Si Wei Wu, Marion van den Bosch, Liam MacPhee, Leo Escano, James S. Blachly, Jonathan E Kolitz, William Blum, Maria R. Baer, Jan-Henning Klusmann, Ann-Kathrin Eisfeld, Arefeh Rouhi, Sharyn D. Baker, Florian Kuchenbauer, Christopher C. Oakes
Journal: Blood
Blood (2023) 142 (Supplement 1): 4126.
https://doi.org/10.1182/blood-2023-188892
Published: 2023
Journal Articles

Modeling Gilteritinib Resistance By Enforced cxcl8a Expression in Zebrafish HSPCs

Konur Oyman, Donn Lee Calkins, Wantong Li, Daelynn Buelow, Sharyn D. Baker, Bradley Wayne Blaser
Journal: Blood
Blood (2023) 142 (Supplement 1): 2710.
https://doi.org/10.1182/blood-2023-189404
Published: 2023
Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Uma M. Borate, Yazan F. Madanat, Cristina Tognon, Shikha Mishra, Andy Kaempf, Prapti A. Patel, Stephen E. Kurtz, Kara Johnson, Sumithira Vasu, Sharyn D. Baker, Bridget A Robinson, Tania Q Vu, Christopher A. Eide, Jessica Minnier, Yiqing Zhang, Peter Clement, Sammantha Avaylon, Thomas Jacob, Rachel Cook, Arpita Gandhi, Jessica T. Leonard, Brandon Hayes-Lattin, Laura F. Newell, Richard T Maziarz, Elie Traer, Ronan T. Swords, Jeffrey W Tyner, Brian J. Druker, Jennifer N. Saultz
Journal: Blood
Blood (2023) 142 (Supplement 1): 1515.
https://doi.org/10.1182/blood-2023-191166
Published: 2023
Journal Articles

Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML

Daelynn R Buelow, PhD, Stanley Pounds, PhD, Yong-Dong Wang, Lei Shi, PhD, Yongjin Li, PhD, David Finkelstein, Sheila A Shurtleff, PhD, Geoffrey A. Neale, PhD, Hiroto Inaba, MD PhD, Raul C. Ribeiro, MD, Dominique Garrison, Shelley Orwick, BS, James S. Blachly, MD, John C. Byrd, MD, Karl Kroll, Tanja A. Gruber, MD PhD, Jeffrey E Rubnitz, MD PhD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 2838.
https://doi.org/10.1182/blood.V128.22.2838.2838
Published: 2016
Journal Articles

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Hiroto Inaba, MD PhD, John C Panetta, PhD, Daelynn R Buelow, PhD, Raul C. Ribeiro, MD, John R. Eckardt, MD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 3937.
https://doi.org/10.1182/blood.V128.22.3937.3937
Published: 2016
Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 3695.
https://doi.org/10.1182/blood.V126.23.3695.3695
Published: 2015
Journal Articles

Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)

Jolieke G van Oosterwijk, PhD, Eric I Zimmerman, PhD, Yong-Dong Wang, PhD, Shelley Orwick, Aksana Vasilyeva, PhD, Katja Schuster, PhD, Abhijit Ramachandran, PhD, Hiroto Inaba, MD PhD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2014) 124 (21): 3620.
https://doi.org/10.1182/blood.V124.21.3620.3620
Published: 2014
Journal Articles

Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

Eric I. Zimmerman, David C. Turner, Jassada Buaboonnam, Shuiying Hu, Shelley Orwick, Michael S. Roberts, Laura J. Janke, Abhijit Ramachandran, Clinton F. Stewart, Hiroto Inaba, Sharyn D. Baker
Journal: Blood
Blood (2013) 122 (22): 3607–3615.
https://doi.org/10.1182/blood-2013-07-513044
Published: 2013
Includes: Supplemental data
Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD
Journal: Blood
Blood (2013) 122 (21): 2680.
https://doi.org/10.1182/blood.V122.21.2680.2680
Published: 2013
Journal Articles

Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.

Hiroto Inaba, MD, PhD, Jeffrey E Rubnitz, MD, PhD, Elaine Coustan-Smith, MS, Lie Li, Brian D Furmanski, PhD, Gerard P Mascara, Sheila A Shurtleff, PhD, Stanley B Pounds, PhD, Ching-Hon Pui, MD, Raul C Ribeiro, MD, Dario Campana, MD, PhD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2010) 116 (21): 1073.
https://doi.org/10.1182/blood.V116.21.1073.1073
Published: 2010
Journal Articles

Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.

Jatinder K. Lamba, Kristine Crews, Stanley Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Sharyn D. Baker, Ching-Hon Pui, Dario Campana, James R. Downing, MD, Jeffrey Rubnitz, Raul C Ribeiro
Journal: Blood
Blood (2009) 114 (22): 114.
https://doi.org/10.1182/blood.V114.22.114.114
Published: 2009
Journal Articles

Inhibition of Class I PI3K Isoforms Restores the Sensitivity of Acute Myelogenous Leukemia Cells to Multi-Tyrosine Kinase Inhibitors in the Bone Marrow Microenvironment.

Akira Shimada, MD, PhD, Hongmei Niu, MD.PhD, Shelley Orwick, Hiroto Inaba, MD, PhD, Jeffrey E Rubnitz, MD, PhD, Dario Campana, MD, PhD, Sharyn D Baker, PharmD.PhD.
Journal: Blood
Blood (2009) 114 (22): 1734.
https://doi.org/10.1182/blood.V114.22.1734.1734
Published: 2009
Journal Articles

Gene Expression Profiling of Acute Myeloid Leukemia Shows Therapeutically Meaningful Patterns of Association with Ara-CTP Pharmacokinetics and Pharmacodynamics

Jatinder K. Lamba, Kristine Crews, Stanley Pounds, Xueyuan Cao, Sharyn D. Baker, Varsha Gandhi, William Plunkett, James R. Downing, Jeffrey Rubnitz, Raul C. Ribeiro
Journal: Blood
Blood (2008) 112 (11): 215.
https://doi.org/10.1182/blood.V112.11.215.215
Published: 2008
Journal Articles

Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.

Akira Shimada, MD, PhD, Shelley Orwick, Hiroyuki Fujisaki, MD., PhD, Dario Campana, MD., PhD, Sharyn D. Baker, PharmD., PhD
Journal: Blood
Blood (2008) 112 (11): 1630.
https://doi.org/10.1182/blood.V112.11.1630.1630
Published: 2008
Journal Articles

Preclinical Evaluation of Sorafenib in Combination with Cytarabine and Clofarabine in Acute Myeloid Leukemia (AML).

Shuiying Hu, PhD, Hongmei Niu, M.S., Shelley Orwick, B.S., Jeffrey Rubnitz, M.D., John Schuetz, Ph.D., Sharyn D. Baker, Pharm D, Ph.D
Journal: Blood
Blood (2007) 110 (11): 4202.
https://doi.org/10.1182/blood.V110.11.4202.4202
Published: 2007